KDM6B WDR5 Peptide for Mesenchymal Stem Cell Osteogenic Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and tooth loss in elderly patients are inadequate, as they often come with side effects and limited bone recovery, and existing restoration methods for tooth loss are non-biological and costly.
Innovation Solution
The use of a bioactive peptide derived from the KDM6B protein complex, specifically targeting the WDR5 and KDM6B interaction, to inhibit senescence and promote osteogenic or odontogenic differentiation of mesenchymal stem cells, thereby enhancing bone and dental tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonates are used to prevent fracture, then fracture incidence rate is reduced by 40-70%, but side effects occur such as acute renal failure, oesophageal cancer, and musculoskeletal pain
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (Runt-related transcription factor 2/Runx2) that controls osteoblast differentiation and bone formation. By intervening at this specific molecular level rather than using broad-spectrum bisphosphonates, the treatment can stimulate bone formation without causing the systemic side effects of conventional drugs.
Solution Approach 2:
The patent uses an intermediary approach by targeting the Runx2 transcription factor as a mediator between the treatment and bone formation. This intermediary mechanism allows for controlled stimulation of osteoblast differentiation through the Wnt/β-catenin signaling pathway, achieving bone anabolism without the harmful effects of direct bisphosphonate action on bone resorption.
2Reliability
If parathyroid hormone is used to stimulate bone formation, then fracture risk is reduced, but osteosarcoma development occurs and treatment duration is limited to 2 years
Solution Approach 1:
The patent applies local quality by specifically targeting the Runx2 transcription factor and Wnt/β-catenin signaling pathway in osteoprogenitor cells to stimulate bone formation. This localized molecular intervention differs from the systemic action of PTH, providing bone anabolism with potentially reduced risk of osteosarcoma by acting through a different molecular mechanism.
Solution Approach 2:
The patent changes the molecular parameters of bone formation stimulation by activating the Wnt/β-catenin pathway and Runx2 expression rather than using PTH. This parameter change in the mechanism of action allows for sustained bone formation stimulation without the same limitations on treatment duration and osteosarcoma risk associated with PTH therapy.
3Reliability
If hormone replacement therapy is used for postmenopausal bone loss, then bone density is maintained, but breast cancer risk increases
Solution Approach 1:
The patent extracts and targets the specific molecular pathway (Wnt/β-catenin/Runx2) that regulates osteoblast differentiation and bone formation. By intervening at this specific molecular level rather than using hormone replacement therapy, the treatment can stimulate bone formation without causing the systemic hormonal side effects including increased breast cancer risk.
Solution Approach 2:
The patent substitutes the hormonal mechanism (mechanics) with a molecular signaling mechanism. Instead of using hormones to maintain bone density, the patent uses targeted molecular intervention at the Runx2 and Wnt/β-catenin pathway level to stimulate bone formation, replacing the hormonal system with a more specific molecular therapy that avoids hormonal side effects.
4Reliability
If non-biological prosthetic restorations are used for tooth loss, then tooth function is restored, but adjacent healthy teeth are damaged and costs are high
Solution Approach 1:
The patent applies self-service by stimulating the patient's own mesenchymal stem cells to differentiate into odontoblasts and regenerate dental tissue. This autologous regeneration approach eliminates the need for non-biological prosthetics that require preparation of adjacent teeth, allowing the body to naturally restore tooth structure without damaging surrounding healthy teeth.
Solution Approach 2:
The patent discards the need for non-biological prosthetic restorations and instead recovers and utilizes the body's own stem cell regenerative capacity. By activating the Wnt/β-catenin/Runx2 pathway in mesenchymal stem cells, the treatment enables natural tooth tissue regeneration, eliminating the harmful effects of prosthetic preparation on adjacent teeth.
Data Source
AI summary
Disclosed in the present invention is an application of lysine (K)-specific demethylase 6B (KDM6B) in regulating and controlling the function of a mesenchymal stem cell. WDR5 is a co-binding protein for negatively regulating and controlling the functions of KDM6B and the MLL1. WDR5 can form a protein complex with KDM6B to inhibit the function of KDM6B, such that expression and functions of genes are regulated and controlled by regulating and controlling the methylation state of downstream senescence and osteogenesis related genes and gene promoter region histone, and finally the effects of regulating stem cell senescence and differentiation functions and bone/tooth tissue repair and regeneration functions are achieved. For a KDM6B and WDR5 binding region sequence, small-molecule polypeptide is researched, developed, and utilized, and the function of the mesenchymal stem cell is regulated by regulating and controlling the binding of a KDM6B/WDR5 complex.